WHO Sounds Alert Over Critical Lack of Obesity Jabs

Fewer than one in 10 patients that would benefit from GLP-1 drugs like Wegovy are able to get them, states the global health agency as it issues its first advice on the therapies.

Considering in excess of 1,000,000,000 people worldwide now obese, it is calling for more widespread and fairer access to these injectable treatments.

According to forecasts, over two billion could be obese by 2030 unless action is taken.

"Our new guidance affirms that obesity is a chronic disease that can be managed with thorough and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and supply-chain constraints are key obstacles to widespread access to the treatments that can aid individuals in losing significant weight, explains the organization.

Skinny Jab Shortage

Even in the present most optimistic case, the manufacturing of GLP-1 therapies could only cover about 100 million people – less than 10% of the global need, per the WHO.

The advice calls on governments and firms to increase access, by strategies such as licensing agreements.

A patent on the active ingredient – the core component of Novo Nordisk's Wegovy – is scheduled to end in a number of countries in 2026.

The Way Weight-Loss Jabs Work

GLP-1 drugs mimick a body's own hormone to slow digestion, suppress the appetite and enhance satiety so people eat less.

Patients usually start to lose weight within a few weeks of commencing the once-weekly jabs.

Studies suggests people may see weight return a year later of stopping the drug, because their normal hunger resume.

Being overweight or obese raises your likelihood for experiencing medical conditions, including type 2 diabetes, heart disease, stroke, and specific malignancies.

Excess weight concerns individuals in all nations and was linked to 3.7 million fatalities worldwide in 2024, according to the WHO.